Hepatitis E virus: epidemiology, molecular mechanisms, clinical manifestations, and emerging therapeutic strategies

i

This article has been updated. A Correction to this article was published on .

i

The Original Article was published on

i

The Original Article was published on

i

This article has been updated

i

This article was retracted on

i

This article has been updated

Abstract

Hepatitis E virus (HEV) is a major global health concern, evolving from a self-limited enteric infection to a complex systemic disease with an expanding burden. This narrative review synthesizes current evidence on HEV virology, epidemiology, zoonotic transmission, and clinical manifestations to inform clinicians, researchers, and policymakers. Despite substantial morbidity among pregnant women and immunosuppressed patients, HEV awareness remains limited, and therapeutic options are constrained. Four genotypes (1–4) show distinct epidemiological patterns; chronic infection occurs primarily in immunocompromised hosts, while extrahepatic manifestations, including neurological and renal complications, are increasingly recognized. Treatment remains limited to ribavirin with variable efficacy and contraindications. The HEV-239 vaccine demonstrates sustained efficacy but requires broader implementation. This review integrates recent advances across virology, clinical practice, and public health, offering a unified framework for understanding HEV as a systemic disease requiring enhanced surveillance, targeted antiviral development, and expanded vaccine deployment within a “One Health” framework.

Keywords

hepatitis E virus / epidemiology / zoonotic transmission / chronic hepatitis E / extrahepatic manifestations / immunopathogenesis / ribavirin therapy / vaccine prevention

CHANGE HISTORY

A Correction to this paper has been published:
https://doi.org

The Retraction Note was updated to reflect reception of statements of disagreement from all authors.

This article has been retracted.Please see the Retraction Notice for more detail:
https://doi.org

References

[1] Balayan MS, Andjaparidze AG, Savinskaya SS, Ketiladze ES, Braginsky DM, Savinov AP, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology. 1983; 20: 23-31.

[2] Reyes GR, Purdy MA, Kim JP, Luk KC, Young LM, Fry KE, et al. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science. 1990; 247: 1335-9.

[3] Tam AW, Smith MM, Guerra ME, Huang CC, Bradley DW, Fry KE, et al. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology. 1991; 185: 120-31.

[4] Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H, et al. Hepatitis E virus infection. Nat Rev Dis Primers. 2017; 3: 17086.

[5] Bradley DW. Hepatitis E virus: a brief review of the biology, molecular virology, and immunology of a novel virus. J Hepatol. 1995; 22: 140-5.

[6] Holla RP, Ahmad I, Ahmad Z, Jameel S. Molecular virology of hepatitis E virus. Semin Liver Dis. 2013; 33: 3-14.

[7] Sari G, Zhu J, Ambardekar C, Yin X, Boonstra A, Feng Z, et al. The Viral ORF3 Protein Is Required for Hepatitis E Virus Apical Release and Efficient Growth in Polarized Hepatocytes and Humanized Mice. J Virol. 2021; 95: e0058521.

[8] Kenney SP, Meng XJ. Hepatitis E Virus Genome Structure and Replication Strategy. Cold Spring Harb Perspect Med. 2019; 9: a031724.

[9] Cao D, Meng XJ. Molecular biology and replication of hepatitis E virus. Emerg Microbes Infect. 2012; 1: e17.

[10] Primadharsini PP, Nagashima S, Okamoto H. Genetic Variability and Evolution of Hepatitis E Virus. Viruses. 2019; 11: 456.

[11] Lu L, Li C, Hagedorn CH. Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev Med Virol. 2006; 16: 5-36.

[12] Benavent S, Carlos S, Reina G. Rocahepevirus ratti as an Emerging Cause of Acute Hepatitis Worldwide. Microorganisms. 2023; 11: 2996.

[13] Sridhar S, Yip CC, Wu S, Chew NF, Leung KH, Chan JF, et al. Transmission of Rat Hepatitis E Virus Infection to Humans in Hong Kong: A Clinical and Epidemiological Analysis. Hepatology. 2021; 73: 10-22.

[14] Rivero-Juarez A, Frias M, Perez AB, Pineda JA, Reina G, Fuentes-Lopez A, et al.; HEPAVIR and GEHEP-014 Study Groups. Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: First report in Europe. J Hepatol. 2022; 77: 326-31.

[15] Sridhar S, Yip CCY, Wu S, Cai J, Zhang AJ, Leung KH, et al. Rat Hepatitis E Virus as Cause of Persistent Hepatitis after Liver Transplant. Emerg Infect Dis. 2018; 24: 2241-50.

[16] Andonov A, Robbins M, Borlang J, Cao J, Hatchette T, Stueck A, et al. Rat Hepatitis E Virus Linked to Severe Acute Hepatitis in an Immunocompetent Patient. J Infect Dis. 2019; 220: 951-5.

[17] Rodriguez C, Marchand S, Sessa A, Cappy P, Pawlotsky J. Orthohepevirus C hepatitis, an underdiagnosed disease? J Hepatol. 2023; 79: e39-41.

[18] Primadharsini PP, Nagashima S, Okamoto H. Mechanism of Cross-Species Transmission, Adaptive Evolution and Pathogenesis of Hepatitis E Virus. Viruses. 2021; 13: 909.

[19] Huang F, Li Y, Yu W, Jing S, Wang J, Long F, et al. Excretion of infectious hepatitis E virus into milk in cows imposes high risks of zoonosis. Hepatology. 2016; 64: 350-9.

[20] Yugo DM, Meng XJ. Hepatitis E virus: foodborne, waterborne and zoonotic transmission. Int J Environ Res Public Health. 2013; 10: 4507-33.

[21] Smith DB, Izopet J, Nicot F, Simmonds P, Jameel S, Meng XJ, et al. Update: proposed reference sequences for subtypes of hepatitis E virus (species Orthohepevirus A) . J Gen Virol. 2020; 101: 692-8.

[22] Lee GH, Tan BH, Teo EC, Lim SG, Dan YY, Wee A, et al. Chronic Infection With Camelid Hepatitis E Virus in a Liver Transplant Recipient Who Regularly Consumes Camel Meat and Milk. Gastroenterology. 2016; 150: 355-7.e3.

[23] Pavio N, Meng Xj, Doceul V. Zoonotic origin of hepatitis E. Curr Opin Virol. 2015; 10: 34-41.

[24] Hewitt PE, Ijaz S, Brailsford SR, Brett R, Dicks S, Haywood B, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet. 2014; 384: 1766-73.

[25] Delage G, Fearon M, Gregoire Y, Hogema BM, Custer B, Scalia V, et al. Hepatitis E Virus Infection in Blood Donors and Risk to Patients in the United States and Canada. Transfus Med Rev. 2019; 33: 139-45.

[26] El Sayed Zaki M, El Aal AA, Badawy A, El-Deeb DR, El-Kheir NYA. Clinicolaboratory study of mother-to-neonate transmission of hepatitis E virus in Egypt. Am J Clin Pathol. 2013; 140: 721-6.

[27] Kumar RM, Uduman S, Rana S, Kochiyil JK, Usmani A, Thomas L. Sero-prevalence and mother-to-infant transmission of hepatitis E virus among pregnant women in the United Arab Emirates. Eur J Obstet Gynecol Reprod Biol. 2001; 100: 9-15.

[28] Rivero-Juarez A, Frias M, Rodriguez-Cano D, Cuenca-López F, Rivero A. Isolation of Hepatitis E Virus From Breast Milk During Acute Infection. Clin Infect Dis. 2016; 62: 1464.

[29] Sintusek P, Thanapirom K, Komolmit P, Poovorawan Y. Eliminating viral hepatitis in children after liver transplants: How to reach the goal by 2030. World J Gastroenterol. 2022; 28: 290-309.

[30] Chen S, Wei F, Wu T, Xia N. Chronic Hepatitis E Virus Infection and Treatment in Organ Transplant Recipients. Bing Du Xue Bao. 2015; 31: 293-8. Chinese.

[31] Wang Y, Ling R, Erker JC, Zhang H, Li H, Desai S, et al. A divergent genotype of hepatitis E virus in Chinese patients with acute hepatitis. J Gen Virol. 1999; 80: 169-77.

[32] Wang Y, Zhang H, Ling R, Li H, Harrison TJ. The complete sequence of hepatitis E virus genotype 4 reveals an alternative strategy for translation of open reading frames 2 and 3. J Gen Virol. 2000; 81: 1675-86.

[33] Zhuang H, Liu CB, Cao XY, Wang GM. Etiological and epidemiological studies of hepatitis E. Acta Universitatis Medicinalis Beijingensis. 1992: 43-6. Chinese.

[34] Zhuang H, Li F, Wang QY, Guo XX, Uchida T, Ai TT, et al. Detection of HEV RNA in Bile of Macaca Mulatta by Polymerase Chain Reaction. Chinese J Exp Clin Pathol. 1992; 9: 111-4. Chinese.

[35] Liao N, Zhang GM, Ging XH, Wang FZ, Zheng H, Wu ZH, et al. Epidemiological analysis of viral hepatitis E in China in 2004~2011. Chinese J Vaccines Immunization. 2013; 19:4. Chinese.

[36] Chen YJ, Cao NX, Xie RH, Ding CX, Chen EF, Zhu HP, et al. Epidemiological investigation of a tap water-mediated hepatitis E virus genotype 4 outbreak in Zhejiang Province, China. Epidemiol Infect. 2016; 144: 3387-99.

[37] Liu Q, Li YF. Spatial and temporal analysis of viral hepatitis in mainland China from 2007 to 2023: implications for targeted public health interventions. Front Public Health. 2025; 13: 1660415.

[38] Huang S, Zhang X, Su Y, Zhuang C, Tang Z, Huang X, et al. Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024; 403: 813-23.

[39] Li SW, Zhao Q, Wu T, Chen S, Zhang J, Xia NS. The development of a recombinant hepatitis E vaccine HEV 239. Hum Vaccin Immunother. 2015; 11: 908-14.

[40] Cao K, Wu X, Yang M, Chen C, Zhang X, Jiang D, et al. Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis. Front Public Health. 2023; 11: 1243408.

[41] Ren X, Wu P, Wang L, Geng M, Zeng L, Zhang J, et al. Changing Epidemiology of Hepatitis A and Hepatitis E Viruses in China, 1990-2014. Emerg Infect Dis. 2017; 23: 276-9.

[42] Man S, Fu J, Yang X, Ma Y, Bao H, Du J, et al. Prevalence and Incidence of Hepatitis E Infection in China. Clin Gastroenterol Hepatol. 2025; 23: 1973-81.e5.

[43] Technical guidelines for prevention and control of hepatitis E [EB/OL] [Internet]. [cited 2026 Feb 10]. Available from: https://www.chinacdc.cn/jkyj/crb2/yl/bdxgy/wxbdxgy/

[44] Brüggemann Y, Klöhn M, Wedemeyer H, Steinmann E. Hepatitis E virus: from innate sensing to adaptive immune responses. Nat Rev Gastroenterol Hepatol. 2024; 21: 710-25.

[45] Yadav KK, Kenney SP. Hepatitis E Virus Immunopathogenesis. Pathogens. 2021; 10: 1180.

[46] Capelli N, Marion O, Dubois M, Allart S, Bertrand-Michel J, Lhomme S, et al. Vectorial Release of Hepatitis E Virus in Polarized Human Hepatocytes. J Virol. 2019; 93: e01207-18.

[47] Prabhu SB, Gupta P, Durgapal H, Rath S, Gupta SD, Acharya SK, et al. Study of cellular immune response against Hepatitis E virus (HEV). J Viral Hepat. 2011; 18: 587-94.

[48] El Costa H, Gouilly J, Abravanel F, Bahraoui E, Peron JM, Kamar N, et al. Effector memory CD8 T cell response elicits Hepatitis E Virus genotype 3 pathogenesis in the elderly. PLoS Pathog. 2021; 17: e1009367.

[49] Kupke P, Werner JM. Hepatitis E Virus Infection-Immune Responses to an Underestimated Global Threat. Cells. 2021; 10: 2281.

[50] Chapuy-Regaud S, Dubois M, Plisson-Chastang C, Bonnefois T, Lhomme S, Bertrand-Michel J, et al. Characterization of the lipid envelope of exosome encapsulated HEV particles protected from the immune response. Biochimie. 2017; 141: 70-9.

[51] Takahashi M, Tanaka T, Takahashi H, Hoshino Y, Nagashima S, Jirintai, et al. Hepatitis E Virus (HEV) strains in serum samples can replicate efficiently in cultured cells despite the coexistence of HEV antibodies: characterization of HEV virions in blood circulation. J Clin Microbiol. 2010; 48: 1112-25.

[52] Nagashima S, Takahashi M, Kobayashi T, Tanggis, Nishizawa T, Nishiyama T, et al. Characterization of the Quasi-Enveloped Hepatitis E Virus Particles Released by the Cellular Exosomal Pathway. J Virol. 2017; 91: e00822-17.

[53] Gouttenoire J, Pollán A, Abrami L, Oechslin N, Mauron J, Matter M, et al. Palmitoylation mediates membrane association of hepatitis E virus ORF3 protein and is required for infectious particle secretion. PLoS Pathog. 2018; 14: e1007471.

[54] Liu X, Liu T, Shao Z, Xiong X, Qi S, Guan J, et al. Palmitoylation-dependent association with Annexin II directs hepatitis E virus ORF3 sorting into vesicles and quasi-enveloped virions. Proc Natl Acad Sci U S A. 2025; 122: e2418751122.

[55] Aggarwal R, Jameel S. Hepatitis E. Hepatology. 2011; 54: 2218-26.

[56] Kamar N, Selves J, Mansuy JM, Ouezzani L, Péron JM, Guitard J, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008; 358: 811-7.

[57] Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009; 361: 1025-7.

[58] Ji C, Xiong C, Wang L, Wang H, Huang P, Gu M, et al. When HEV infection meets organ transplantation. Int J Surg. 2025; 111: 7114-24.

[59] von Felden J, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, et al. The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study. J Hepatol. 2019; 71: 465-72.

[60] Di Bartolomeo S, Carubbi F, Cipriani P. Hepatitis E Virus and rheumatic diseases: what do rheumatologists need to know? BMC Rheumatol. 2020; 4: 51.

[61] Nan Y, Wu C, Zhao Q, Sun Y, Zhang YJ, Zhou EM. Vaccine Development against Zoonotic Hepatitis E Virus: Open Questions and Remaining Challenges. Front Microbiol. 2018; 9: 266.

[62] Xu B, Yu HB, Hui W, He JL, Wei LL, Wang Z, et al. Clinical features and risk factors of acute hepatitis E with severe jaundice. World J Gastroenterol. 2012; 18: 7279-84.

[63] Chen J, Yin D, Zhou Y, Bai Y, Yan L, Yuan X, et al. Risk factors analysis for progression to severe hepatitis in acute hepatitis E: a retrospective study of 146 hospitalized cases. BMC Infect Dis. 2025; 26: 37.

[64] Zhang S, Chen C, Peng J, Li X, Zhang D, Yan J, et al. Investigation of underlying comorbidities as risk factors for symptomatic human hepatitis E virus infection. Aliment Pharmacol Ther. 2017; 45: 701-13.

[65] Azman AS, Paul KK, Bhuiyan TR, Koyuncu A, Salje H, Qadri F, et al. Hepatitis E in Bangladesh: Insights From a National Serosurvey. J Infect Dis. 2021; 224: S805-12.

[66] Amanya G, Kizito S, Nabukenya I, Kalyango J, Atuheire C, Nansumba H, et al. Risk factors, person, place and time characteristics associated with Hepatitis E Virus outbreak in Napak District, Uganda. BMC Infect Dis. 2017; 17: 451.

[67] Ofori-Asenso R, Agyeman AA. Hepatitis E infection among Ghanaians: a systematic review. Infect Dis Poverty. 2017; 6: 29.

[68] Navaneethan U, Al Mohajer M, Shata MT. Hepatitis E and pregnancy: understanding the pathogenesis. Liver Int. 2008; 28: 1190-9.

[69] Bonvicino CR, Moreira MA, Soares MA. Hepatitis B virus lineages in mammalian hosts: potential for bidirectional cross-species transmission. World J Gastroenterol. 2014; 20: 7665-74.

[70] Buescher G, Ozga AK, Lorenz E, Pischke S, May J, Addo MM, et al. Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta-analysis. Liver Int. 2021; 41: 449-55.

[71] Kamar N, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology. 2011; 140: 1481-9.

[72] Ma Z, de Man RA, Kamar N, Pan Q. Chronic hepatitis E: Advancing research and patient care. J Hepatol. 2022; 77: 1109-23.

[73] Harun-Or-Rashid M, Akbar SM, Takahashi K, Al-Mahtab M, Khan MS, Alim MA, et al. Epidemiological and molecular analyses of a non-seasonal outbreak of acute icteric hepatitis E in Bangladesh. J Med Virol. 2013; 85: 1369-76.

[74] Centers for Disease Control and Prevention (CDC). Hepatitis E among U.S. travelers, 1989-1992. MMWR Morb Mortal Wkly Rep. 1993; 42: 1-4.

[75] Morrow RH Jr, Smetana HF, Sai FT, Edgcomb JH. Unusual features of viral hepatitis in Accra, Ghana. Ann Intern Med. 1968; 68: 1250-64.

[76] Jameel S, Durgapal H, Habibullah CM, Khuroo MS, Panda SK. Enteric non-A, non-B hepatitis: epidemics, animal transmission, and hepatitis E virus detection by the polymerase chain reaction. J Med Virol. 1992; 37: 263-70.

[77] Fousekis FS, Mitselos IV, Christodoulou DK. Extrahepatic manifestations of hepatitis E virus: An overview. Clin Mol Hepatol. 2020; 26: 16-23.

[78] Geurtsvankessel CH, Islam Z, Mohammad QD, Jacobs BC, Endtz HP, Osterhaus AD. Hepatitis E and Guillain-Barre syndrome. Clin Infect Dis. 2013; 57: 1369-70.

[79] Jha AK, Kumar G, Dayal VM, Ranjan A, Suchismita A. Neurological manifestations of hepatitis E virus infection: An overview. World J Gastroenterol. 2021; 27: 2090-104.

[80] Kamar N, Bendall RP, Peron JM, Cintas P, Prudhomme L, Mansuy JM, et al. Hepatitis E virus and neurologic disorders. Emerg Infect Dis. 2011; 17: 173-9.

[81] Dalton HR, Kamar N, van Eijk JJ, Mclean BN, Cintas P, Bendall RP, et al. Hepatitis E virus and neurological injury. Nat Rev Neurol. 2016; 12: 77-85.

[82] Khan M, Khan Z, Altaf A, Bibi S, Batool I, Naamani AER, et al. Acute hepatitis E virus infection as a trigger for postinfectious IgA nephropathy: A rare case report. Medicine (Baltimore). 2025; 104:e46341.

[83] Villa A, Gigante A, Pellicano C, Radovic K, Giannakakis K, Casato M, et al. Renal Involvement in Mixed Cryoglobulinemic Vasculitis: Current Perspectives. J Clin Med. 2025; 14: 4369.

[84] Masset C, Le Turnier P, Bressollette-Bodin C, Renaudin K, Raffi F, Dantal J. Virus-Associated Nephropathies: A Narrative Review. Int J Mol Sci. 2022; 23: 12014.

[85] Wang H, Hu L, Zheng Y, Zhao X, Yang J, Wang C, et al. Acute hepatitis with synchronous acalculous cholecystitis and pancreatitis in a patient with Epstein-Barr viral infection: a case report. J Med Case Rep. 2026; 20: 100.

[86] Malakar S, Kumar S, Rungta S, Kothalkar S, Kumar A, Kohli KP, et al. Acute Viral Hepatitis E Presenting With Bell’s Palsy and Acute Pancreatitis: A Case Report. Cureus. 2024; 16: e73260.

[87] Haffar S, Bazerbachi F, Garg S, Lake JR, Freeman ML. Frequency and prognosis of acute pancreatitis associated with acute hepatitis E: A systematic review. Pancreatology. 2015; 15: 321-6.

[88] Pischke S, Peron J, von Wulffen M, von Felden J, Höner Zu Siederdissen C, Fournier S, et al. Chronic Hepatitis E in Rheumatology and Internal Medicine Patients: A Retrospective Multicenter European Cohort Study. Viruses. 2019; 11: 186.

[89] Kamar N, Marion O, Abravanel F, Izopet J, Dalton HR. Extrahepatic manifestations of hepatitis E virus. Liver Int. 2016; 36: 467-72.

[90] Bose PD, Das BC, Hazam RK, Kumar A, Medhi S, Kar P. Evidence of extrahepatic replication of hepatitis E virus in human placenta. J Gen Virol. 2014; 95: 1266-71.

[91] Orozco-Cordoba J, Mazas C, Du Pont G, Lamoyi E, Cárdenas G, Fierro NA. Viral Biology and Immune Privilege in the Development of Extrahepatic Manifestations During Hepatitis E Virus Infection. Viral Immunol. 2023; 36: 627-41.

[92] Trémeaux P, Lhomme S, Chapuy-Regaud S, Peron JM, Alric L, Kamar N, et al. Performance of an antigen assay for diagnosing acute hepatitis E virus genotype 3 infection. J Clin Virol. 2016; 79: 1-5.

[93] Hepatitis E virus infection [Internet]. UpToDate; c2026 [cited 2025 May 6]. Available from: https://www.uptodate.com/contents/hepatitis-e-virus-infection..

[94] Favorov MO, Fields HA, Purdy MA, Yashina TL, Aleksandrov AG, Alter MJ, et al. Serologic identification of hepatitis E virus infections in epidemic and endemic settings. J Med Virol. 1992; 36: 246-50.

[95] Favorov MO, Khudyakov YE, Mast EE, Yashina TL, Shapiro CN, Khudyakova NS, et al. IgM and IgG antibodies to hepatitis E virus (HEV) detected by an enzyme immunoassay based on an HEV-specific artificial recombinant mosaic protein. J Med Virol. 1996; 50: 50-8.

[96] Damiris K, Aghaie Meybodi M, Niazi M, Pyrsopoulos N. Hepatitis E in immunocompromised individuals. World J Hepatol. 2022; 14: 482-94.

[97] Baylis SA, Hanschmann KM, Blümel J, Nübling CM ; HEV Collaborative Study Group. Standardization of hepatitis E virus (HEV) nucleic acid amplification technique-based assays: an initial study to evaluate a panel of HEV strains and investigate laboratory performance. J Clin Microbiol. 2011; 49: 1234-9.

[98] Khudyakov Y, Kamili S. Serological diagnostics of hepatitis E virus infection. Virus Res. 2011; 161: 84-92.

[99] Khuroo MS, Khuroo MS. Hepatitis E: an emerging global disease-from discovery towards control and cure. J Viral Hepat. 2016; 23: 68-79.

[100] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol. 2018; 68: 1256-71.

[101] Zhao C, Tao S, Lu M, Li W, Zhao H, Sun S, et al. Evaluation of urinary hepatitis E virus antigen colloidal gold immunochromatographic assay in clinical diagnosis of hepatitis E virus infection. J Clin Virol. 2025; 179: 105825.

[102] Gu T, Zheng CY, Deng YQ, Yang XF, Bao WM, Tang YM. Systematic Evaluation of Guidelines for the Diagnosis and Treatment of Hepatitis E Virus Infection. J Clin Transl Hepatol. 2024; 12: 739-49.

[103] Kinast V, Burkard TL, Todt D, Steinmann E. Hepatitis E Virus Drug Development. Viruses. 2019; 11: 485.

[104] De Winter BCM, Hesselink DA, Kamar N. Dosing ribavirin in hepatitis E-infected solid organ transplant recipients. Pharmacol Res. 2018; 130: 308-15.

[105] Kamar N, Izopet J, Tripon S, Bismuth M, Hillaire S, Dumortier J, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med. 2014; 370: 1111-20.

[106] Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis. 2004; 43: 140-6.

[107] Kamar N, Rostaing L, Abravanel F, Garrouste C, Esposito L, Cardeau-Desangles I, et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis. 2010; 50: e30-3.

[108] Haagsma EB, Riezebos-Brilman A, van den Berg AP, Porte RJ, Niesters HG. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transpl. 2010; 16: 474-7.

[109] Kamar N, Abravanel F, Garrouste C, Cardeau-Desangles I, Mansuy JM, Weclawiak H, et al. Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. Nephrol Dial Transplant. 2010; 25: 2792-5.

[110] Zhang X, Klöhn M, Ouwerkerk-Mahadevan S, Jagst M, Vereyken L, Verboven P, et al. A Pangenotypic Hepatitis E Virus Replication Inhibitor With High Potency in a Rat Infection Model. Gastroenterology. 2025; 168: 769-83.e12.

[111] Klöhn M, Burkard T, Janzen J, Haase JA, Gömer A, Fu R, et al. Targeting cellular cathepsins inhibits hepatitis E virus entry. Hepatology. 2024; 80: 1239-51.

[112] Wang Y, Zhou X, Debing Y, Chen K, Van Der Laan LJ, Neyts J, et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology. 2014; 146: 1775-83.

[113] Pischke S, Stiefel P, Franz B, Bremer B, Suneetha PV, Heim A, et al. Chronic hepatitis e in heart transplant recipients. Am J Transplant. 2012; 12: 3128-33.

[114] Manka P, Bechmann LP, Coombes JD, Thodou V, Schlattjan M, Kahraman A, et al. Hepatitis E Virus Infection as a Possible Cause of Acute Liver Failure in Europe. Clin Gastroenterol Hepatol. 2015; 13: 1836-42.e2.

[115] Todt D, Gisa A, Radonic A, Nitsche A, Behrendt P, Suneetha PV, et al. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut. 2016; 65: 1733-43.

[116] Debing Y, Gisa A, Dallmeier K, Pischke S, Bremer B, Manns M, et al. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. Gastroenterology. 2014; 147: 1008-11.e7.

[117] Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010; 376: 895-902.

[118] Kao CM, Rostad CA, Nolan LE, Peters E, Kleinhenz J, Sherman JD, et al. A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults. J Infect Dis. 2024; 230: 1093-101.

[119] Nesbitt RC, Kinya Asilaza V, Alvarez C, Gitahi P, Nkemenang P, Duncker J, et al. The effectiveness of two doses of recombinant hepatitis E vaccine in response to an outbreak in Bentiu, South Sudan: a case-control and bias indicator study. Lancet Infect Dis. 2025; 25: 537-47.

[120] Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology. 2012; 55: 988-97.

[121] Kim SB, Agampodi S, Saluja T, Sahastrabuddhe S, Kim HS, Kim JH, et al. Hepatitis E vaccine landscape update 2025. Expert Rev Vaccines. 2025; 24: 1-16.

[122] EFSA Panel on Biological Hazards (BIOHAZ); Ricci A, Allende A, Bolton D, Chemaly M, Davies R, Fernandez Escamez PS, et al. Public health risks associated with hepatitis E virus (HEV) as a food-borne pathogen. EFSA J. 2017; 15:e04886.

[123] Meng XJ. Zoonotic and foodborne transmission of hepatitis E virus. Semin Liver Dis. 2013; 33: 41-9.

[124] Domanović D, Tedder R, Blümel J, Zaaijer H, Gallian P, Niederhauser C, et al. Hepatitis E and blood donation safety in selected European countries: a shift to screening? Euro Surveill. 2017; 22: 30514.